Table 3 Univariate and Multivariable analyses of overall survival.

From: MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab

Variables

Univariate analysis

Multivariate analysis

HR (95% CI)

p

HR (95% CI)

p

Age (≥60 vs. <60)

1.68 (1.03–4.74)

0.12

  

Gender

   Male vs. Female

2.72 (1.63–8.21)

0.01

4.79 (0.81–5.23)

0.09

Smokinga

2.13 (1.22–5.64)

0.07

1.56 (0.83–4.52)

0.28

T stage (T1-2 vs. 3-4)

0.45 (0.19–0.68)

0.04

0.36 (0.19–4.67)

0.31

N stage (N0-1 vs. 2-3)

0.33 (0.11–0.56)

0.034

0.42 (0.28–1.53)

0.17

EGFR status

NA

Reference

   

Wild-type

0.54 (0.24–1.24)

0.15

0.48 (0.34–1.67)

0.69

Mutant

0.48 (0.20–1.16)

0.10

0.31 (0.14–2.21)

0.77

BM status

   BM vs. non-BM

1.23 (1.02–3.14)

0.028

1.55 (1.02–3.41)

0.046

First-line chemo cycles

   4 vs. 6

0.88 (0.55–1.34)

0.09

0.46 (0.13–1.62)

0.23

TRT

0.73 (0.48–0.92)

<0.01

0.52 (0.16–0.97)

0.026

MTAP expression

   Low vs. High

1.78 (1.03–3.17)

0.01

1.36 (1.01–4.48)

0.038

  1. BM, brain metastasis; TRT, thoracic radiation. Smokinga: Former/current vs. never.
Back to article page